Zetia Cost in Indiana 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Indiana in 2026?

Brand-name Zetia carries a manufacturer list price near $380 per month, but almost no Indiana patient paying attention to their options pays that figure. Generic ezetimibe 10 mg is widely available at Indiana retail chains for roughly $15 per month cash-pay in 2026, and GoodRx-style discount programs can push that price even lower at specific zip codes.

The price gap between brand and generic here is wide. Merck's branded Zetia received FDA approval as an adjunct to diet, exercise, and statin therapy for reducing LDL-C, and the active moiety has been off-patent long enough that six or more generic manufacturers now compete in the US market. The FDA's current reference for approved ezetimibe products is maintained in the Orange Book.

Price varies by pharmacy chain, quantity, and whether a coupon code or discount card is applied. CVS, Walgreens, Kroger, and Walmart pharmacies across Indianapolis, Fort Wayne, and Evansville all stock generic ezetimibe. Walmart's $4/$10 generic list historically includes ezetimibe in certain states; Indiana patients should verify enrollment at the pharmacy counter. The clinical evidence for ezetimibe's LDL-lowering effect is well-established: in IMPROVE-IT (N=18,144), adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL-C by an additional 24% compared to simvastatin alone, and reduced the composite cardiovascular endpoint by 6.4% relative risk reduction over 7 years. IMPROVE-IT, NEJM 2015, PMID 26039521.

That cardiovascular outcome data has made ezetimibe a standard second-line agent after statins in ACC/AHA lipid guidelines. The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapy explicitly lists ezetimibe as the first nonstatin to add when LDL-C remains above goal on maximally tolerated statin therapy. ACC/AHA 2022 nonstatin pathway.

The practical takeaway: $15/month is a realistic cash price for Indiana patients who use a generic and apply a discount card. The $380 brand price is avoidable in almost every case.

Does Indiana Medicaid Cover Ezetimibe?

Indiana Medicaid does not cover Zetia or generic ezetimibe as a routine hyperlipidemia treatment. Coverage is restricted to members with a documented type 2 diabetes diagnosis. That policy distinguishes Indiana from states that provide broader statin-adjunct coverage, and it directly affects uninsured and Medicaid-only patients who are trying to manage LDL without a diabetes comorbidity.

For patients who do qualify under the T2D carve-out, ezetimibe appears on the Indiana Medicaid preferred drug list with a $0 or low cost-share. Providers should document the type 2 diabetes ICD-10 code (E11.xx) clearly on the prescription to avoid prior-authorization delays. Indiana Medicaid preferred drug list policies are maintained by the Indiana Family and Social Services Administration.

The Centers for Medicare and Medicaid Services publishes state-level Medicaid drug coverage data through its drug rebate program transparency portal. CMS Medicaid drug rebate program data. Patients without a T2D diagnosis who cannot afford the cash price have three practical alternatives: a manufacturer savings program, a 503A compounded formulation, or a state pharmaceutical assistance program.

Indiana's Healthy Indiana Plan (HIP 2.0) follows the same preferred drug list restrictions as traditional Medicaid. Members enrolled in HIP Plus with a chronic condition management account sometimes receive different cost-sharing, but the therapeutic coverage criteria for ezetimibe remain the same. A prescriber letter of medical necessity can support a formulary exception request, though approval rates vary by managed care organization.

Which Indiana Insurance Plans Cover Zetia or Generic Ezetimibe?

Most commercial insurance plans in Indiana place generic ezetimibe on Tier 1 or Tier 2, meaning the copay typically runs $5 to $45 per 30-day supply depending on plan design. Brand Zetia usually lands on Tier 3 or Tier 4 with a cost-share of $60 to $150 or higher, plus potential step-therapy requirements demanding a trial of the generic first.

Anthem Blue Cross Blue Shield Indiana, Cigna, UnitedHealthcare, and Aetna all operate fully insured commercial plans in Indiana. Each maintains a formulary that, as of 2025-2026 plan years, includes generic ezetimibe as a preferred generic. Step-therapy protocols requiring a documented statin trial before ezetimibe authorization are common on employer-sponsored plans. The Indiana Department of Insurance provides a consumer guide to formulary review rights for state-regulated plans. IDOI consumer resources.

Medicare Part D plans vary considerably. The 2025 Medicare Prescription Drug Plan Finder through CMS allows Indiana seniors to compare ezetimibe coverage across all Part D plans available in their county. Medicare plan finder. Generic ezetimibe appears on the formulary of most Part D plans, typically as Tier 1 preferred generic with a $0 to $10 copay during the deductible-waived initial coverage phase.

The AHA scientific statement on the cost-effectiveness of LDL-lowering therapy notes that ezetimibe's generic pricing makes it one of the few adjunct lipid therapies with a cost-effectiveness ratio well below the $100,000 per QALY threshold used in US coverage decisions. AHA cost-effectiveness statement, Circulation 2019. That evidence base supports formulary inclusion, and most commercial payers have responded accordingly.

Patients facing a Tier 3 brand placement for Zetia can ask their prescriber to write "dispense as written" only if there is a clinical reason to avoid the generic; otherwise, switching to the generic formulation at the pharmacy counter is the simplest cost-reduction step.

Is Compounded Ezetimibe Legal in Indiana?

Compounded ezetimibe is legal in Indiana when prepared by a state-licensed 503A pharmacy operating under applicable federal and Indiana Board of Pharmacy rules. The cost to the patient can be as low as $0 per month depending on the compounding pharmacy's pricing model and any applicable clinical program.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drug products on a patient-specific basis when a valid prescription exists and the compounding does not copy a commercially available product in a way that violates FDA policy. FDA 503A compounding overview. Ezetimibe's commercial availability as a cheap generic creates a nuanced question: the FDA's guidance on compounding of commercially available drugs requires a clinical rationale for the compounded version when an FDA-approved alternative exists. FDA guidance on compounding commercially available drugs.

Prescribers in Indiana who write for compounded ezetimibe typically do so when a patient needs an altered dosage form, such as a liquid suspension for dysphagia, or when a bundled clinical program provides it at no cost as part of cardiovascular risk management. The Indiana Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. Indiana Board of Pharmacy.

A reasonable prescribing framework for ezetimibe access in Indiana:

1. Check generic ezetimibe cash price with a discount card first (target <$20/month).
2. If the patient has T2D, confirm Indiana Medicaid or HIP 2.0 coverage before billing cash.
3. For commercial insurance, confirm the tier and whether a prior authorization for the generic is required.
4. If cost remains prohibitive and a clinical rationale exists, evaluate 503A compounding through a licensed Indiana pharmacy.
5. Apply the Merck Zetia savings card only if the patient is commercially insured and requires the brand product for a documented reason.

Patients should confirm that their chosen compounding pharmacy holds an active Indiana license and is not on the FDA's list of pharmacies subject to a federal injunction. FDA list of compounding pharmacies subject to injunctions.

How Does Telehealth Prescribing of Ezetimibe Work in Indiana?

Telehealth prescribing of ezetimibe is fully permitted in Indiana for established and new patient encounters under current state telemedicine rules. An Indiana-licensed prescriber, including physicians, nurse practitioners, and physician assistants with prescriptive authority, may evaluate a patient via synchronous audio-video visit and issue a valid ezetimibe prescription.

Indiana Code 25-1-9.5 governs telehealth practice standards, requiring that telehealth prescribing meet the same standard of care as in-person care. Indiana Code 25-1-9.5 telehealth statute. Prescribers must establish a proper patient-provider relationship, review relevant lipid panel results (a baseline fasting lipid panel is standard of care before initiating any LDL-lowering therapy), and document clinical decision-making.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends fasting lipid panels to classify cardiovascular risk and guide initiation of LDL-lowering therapy. 2018 ACC/AHA Cholesterol Guideline, PMID 30586774. Telehealth providers in Indiana commonly use LabCorp or Quest Diagnostics patient service centers for laboratory orders, allowing the patient to complete a blood draw locally before a telehealth consult.

Ezetimibe is not a controlled substance and does not require DEA special registration for telehealth prescribing, which simplifies the process considerably compared to controlled substances. The prescription can be sent electronically to any Indiana pharmacy or compounding pharmacy via e-prescribing systems. DEA telemedicine prescribing rules for non-controlled substances.

Indiana telehealth platforms, including HealthRX and others, can legally prescribe generic ezetimibe, brand Zetia, or a compounded ezetimibe product provided the prescriber holds an active Indiana license and the clinical encounter meets standard-of-care documentation requirements.

What Are the Cheapest Ways to Get Ezetimibe in Indiana?

Generic ezetimibe at $15 per month cash-pay is already among the most affordable LDL-lowering options in Indiana, but specific strategies can reduce cost further.

Discount card programs. GoodRx, RxSaver, Blink Health, and similar discount card services negotiate rates with pharmacy benefit managers. At select Indiana pharmacies, these cards bring the 30-tablet supply of ezetimibe 10 mg below $10. The specific price depends on the pharmacy and ZIP code. Discount cards cannot be combined with insurance, so patients should compare their insurance copay against the discount card price before applying one.

Merck savings card for brand Zetia. Merck operates a patient savings program for Zetia that may reduce out-of-pocket cost for commercially insured patients to as low as $5 per month for a defined period. The program explicitly excludes patients covered by federal programs including Medicare, Medicaid, TRICARE, and VA. Patients should visit Merck's official site or call 1-877-264-2440 to verify current Indiana-specific terms, as program terms change annually.

340B program pharmacies. Federally qualified health centers (FQHCs) in Indiana operating under the 340B Drug Pricing Program can dispense ezetimibe at reduced acquisition cost to eligible low-income patients. The Health Resources and Services Administration maintains the 340B covered entity database. HRSA 340B database. Major Indiana 340B participants include Eskenazi Health in Indianapolis and similar safety-net systems across the state.

Mail-order pharmacy. Most Indiana commercial insurance plans include a 90-day mail-order supply for a two-copay cost, effectively reducing per-dose cost by one-third. For a Tier 1 generic with a $10 copay, a 90-day mail supply might cost $20 rather than $30 over three monthly fills.

State pharmaceutical assistance programs. Indiana does not operate a broad state pharmaceutical assistance program (SPAP) comparable to those in New York or New Jersey. However, the NeedyMeds database lists Indiana-specific patient assistance resources. NeedyMeds Indiana resources. Merck's own patient assistance program (MAP) provides Zetia at no cost to uninsured patients meeting income criteria, generally below 400% of the federal poverty level.

The Clinical Case for Ezetimibe: Why This Drug Matters

Ezetimibe reduces LDL-C by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, blocking cholesterol absorption. That mechanism is distinct from statins, which inhibit hepatic cholesterol synthesis, making ezetimibe useful as a complementary agent. Ezetimibe mechanism review, PMID 16387090.

IMPROVE-IT (N=18,144) enrolled patients with acute coronary syndrome and randomized them to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg. At 7 years, the combination group achieved a median LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only group, and the primary cardiovascular composite endpoint was reduced from 34.7% to 32.7% (absolute risk reduction 2.0%, hazard ratio 0.936, P<0.001 by log-rank). IMPROVE-IT, PMID 26039521.

The ACC/AHA writing committee that authored the 2018 Blood Cholesterol Guideline stated: "In patients with clinical ASCVD whose LDL-C level remains at or above goal on maximally tolerated statin therapy, ezetimibe is recommended as first additional LDL-C-lowering therapy." 2018 ACC/AHA Guideline, PMID 30586774. That explicit recommendation underpins most commercial and Medicare formulary inclusion decisions.

Beyond IMPROVE-IT, the SHARP trial (N=9,270) evaluated ezetimibe plus simvastatin in chronic kidney disease patients and demonstrated a 17% proportional reduction in major atherosclerotic events compared with placebo. SHARP trial, PMID 21663949. That finding extends the evidence base to a population common in Indiana, where chronic kidney disease prevalence tracks with diabetes and hypertension rates above the national average. CDC chronic kidney disease data.

Safety data from these trials and from post-marketing surveillance submitted to the FDA shows ezetimibe is generally well-tolerated. Myopathy rates are not meaningfully elevated above placebo when ezetimibe is used as monotherapy, though combination with statins requires the standard statin myopathy monitoring. FDA ezetimibe prescribing information.

Liver enzyme elevations occur in less than 1% of patients in monotherapy trials, similar to placebo rates. The ACC/AHA cholesterol guideline does not recommend routine liver function testing during ezetimibe therapy in the absence of symptoms. ACC/AHA 2018 Guideline on Blood Cholesterol, PMID 30586774.

Ezetimibe Dosing and Administration for Indiana Patients

The FDA-approved dose of ezetimibe is 10 mg orally once daily, taken with or without food, with no renal or hepatic dose adjustment required for mild-to-moderate impairment. FDA ezetimibe label. Severe hepatic impairment is a contraindication. The drug is available as a single-agent 10 mg tablet and as a fixed-dose combination with simvastatin (Vytorin) or with atorvastatin (in certain markets).

Onset of LDL-C reduction is typically seen within 2 weeks of starting therapy, and a fasting lipid panel at 4 to 12 weeks after initiation is standard practice per ACC/AHA guidelines to confirm response and guide any further therapeutic adjustments. NCBI StatPearls ezetimibe pharmacology.

Drug interactions are limited compared to statins. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55%; ezetimibe should be taken either 2 hours before or 4 hours after a bile acid sequestrant. Cyclosporine significantly increases ezetimibe exposure and requires dose monitoring. NCBI StatPearls ezetimibe pharmacology.

How Indiana Patients Can Get Started Today

An Indiana resident with an LDL-C above their ACC/AHA risk-based goal on maximally tolerated statin therapy has a straightforward path to ezetimibe. The steps are concrete.

First, confirm a current fasting lipid panel is on file (within 3 months is typical for clinical decision support). Second, contact an Indiana-licensed prescriber, either in person or via telehealth. Third, send the prescription to the lowest-cost dispensing option: a retail pharmacy with a discount card for cash-pay patients, the mail-order benefit for commercially insured patients, or a 503A compounding pharmacy if the clinical and legal criteria are satisfied.

The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapy states that ezetimibe should be the first nonstatin added when LDL-C remains elevated despite statin therapy, before escalating to PCSK9 inhibitors or other higher-cost biologics. ACC 2022 Expert Consensus, JACC. PCSK9 inhibitors (evolocumab, alirocumab) cost $5,000 to $7,000 per year even with rebates; ezetimibe at $180 per year generic cash-pay is the rational first step.

Indiana patients with documented ASCVD, an LDL-C above 70 mg/dL on maximally tolerated statin therapy, and no contraindications should be offered ezetimibe 10 mg daily as the next therapeutic move.